8 Mar 2012 07:00
OXFORD BIOMEDICA PLC
Director / PDMR dealings
Oxford, UK - 8 March 2012: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, was informed on 7 March 2012 that two of its directors had acquired ordinary shares of 1p each ("Ordinary Shares") at a price of 3.022273p per Ordinary Share.
|
|
|
|
|
|
| Interest after purchase | ||
Director / PDMR |
| Title |
| Price | Number of Ordinary Shares acquired on 07 March 2012 |
| Number of Ordinary Shares |
| % of total issued share capital |
Timothy Watts |
| CFO |
| 3.022273p | 1,000,000 |
| 1,000,000 |
| 0.1% |
Paul Blake |
| NED |
| 3.022273p | 100,000 |
| 300,000 |
| 0.03% |
The issued share capital of the Company is 944,875,557 1p ordinary shares.
For further information please contact:
For further information, please contact: | |
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer Lara Mott, Head of Corporate Communications |
Tel: +44 (0)1865 783 000 |
Singer Capital Markets Limited: Shaun Dobson/Claes Spång |
Tel: +44 (0)20 3205 7500 |
Oxford Biomedica (OXB)